Just trying to see if there is anything other than a takeover rumour that will get this stock going again.
In the near-term, I think we might get a bump from the commercialization of cabo - it's been downplayed by MM so much that it should be guaranteed to meet or exceed expectations. ASCO abstracts are due end of this week? In recent years, ASCO has been all about the build-up and then selling on the news. It will be interesting to see if EXEL has anything interesting to present.
Does anyone know if there are any milestones related to Roche that we could expect - in terms of a trial update, etc?